Literature DB >> 9519881

Isolation of canine p53 cDNA and detailed characterization of the full length canine p53 protein.

N Veldhoen1, J Milner.   

Abstract

The p53 tumour suppressor protein plays a central role in the maintenance of genomic integrity. Mutations of the p53 gene are found in a number of canine cancers and many contribute to tumour formation. Here we describe isolation and expression of the complete wild type canine p53 cDNA. The encoded full length canine p53 protein displays strong sequence homology with p53 proteins from other higher vertebrates. Canine p53 protein produced in vitro was shown to recognize and bind to p53-specific DNA targets derived from the p21 and GADD45 promoters and to a consensus p53 binding site. We also show that canine p53 associates with oligonucleotides representing damaged DNA sites and undergoes proteolytic cleavage similar to that described for murine and human p53 proteins. Finally, we show that the canine p53 protein is able to transcriptionally activate a p53-dependent reporter gene in vivo. The results suggest that canine p53 is similar both in structure and function to human p53 and that canine cancer may provide a useful clinical model in the search for effective anti-cancer therapies based on p53.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9519881     DOI: 10.1038/sj.onc.1201863

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  6 in total

1.  Allogeneic astrocytoma in immune competent dogs.

Authors:  M E Berens; A Giese; J R Shapiro; S W Coons
Journal:  Neoplasia       Date:  1999-06       Impact factor: 5.715

2.  Novel canine tumour suppressor gene p53 mutations in cases of skin and mammary neoplasms.

Authors:  B Mayr; M Reifinger; K Alton
Journal:  Vet Res Commun       Date:  1999-08       Impact factor: 2.459

3.  TP53 Polymorphisms allow for genetic sub-grouping of the canine transmissible venereal tumor.

Authors:  Abel Sánchez-Servín; Simón Martínez; Emilio Córdova-Alarcon; Raúl Fajardo
Journal:  J Vet Sci       Date:  2009-12       Impact factor: 1.672

4.  Enrofloxacin enhances the effects of chemotherapy in canine osteosarcoma cells with mutant and wild-type p53.

Authors:  D York; S S Withers; K D Watson; K W Seo; R B Rebhun
Journal:  Vet Comp Oncol       Date:  2016-06-23       Impact factor: 2.613

5.  Identification of tumour-associated and germ line p53 mutations in canine mammary cancer.

Authors:  N Veldhoen; J Watterson; M Brash; J Milner
Journal:  Br J Cancer       Date:  1999-10       Impact factor: 7.640

Review 6.  DNA damage response proteins in canine cancer as potential research targets in comparative oncology.

Authors:  Beatriz Hernández-Suárez; David A Gillespie; Aleksandra Pawlak
Journal:  Vet Comp Oncol       Date:  2022-01-10       Impact factor: 2.385

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.